Key result
Obesity is linked to lower than expected BNP and NT-proBNP levels in HF, complicating clinical interpretation.
Why the study?
BNP and NT-proBNP levels are lower than expected in obese patients with heart failure, but the underlying mechanisms and clinical consequences are not fully elucidated.
Clinicians must be aware that obesity lowers BNP/NT-proBNP levels in heart failure patients, potentially confounding diagnosis and prognostic assessment.
Supports cautious natriuretic peptide interpretation in obese HF; leaves open whether obesity-adjusted thresholds improve accuracy.
Since its discovery in 1988, B-type natriuretic peptide (BNP) and later its amino-terminal counterpart NT-proBNP have been thoroughly investigated and have become an essential clinical tool used in everyday practice for the diagnosis and prognostic assessment of patients with heart failure. However, one of the main pitfalls in the clinical interpretation of BNP/NT-proBNP levels is the concurrent presence of obesity. Many studies have demonstrated that BNP/NT-proBNP levels are lower than expected in obese patients even if the underlying mechanisms have not been fully elucidated yet. This article will review the physiology of BNP/NT-proBNP and their use in the clinical setting. We will then explore the pathophysiology of the association between obesity and low BNP/NT-proBNP levels to conclude with potential clinical consequences in patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Reinmann et al. (2020) conducted a review in Heart failure and obesity. Obesity was evaluated. Obesity is associated with lower than expected BNP and NT-proBNP levels in patients with heart failure, complicating their clinical interpretation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: